TY  - JOUR
AU  - Barriocanal-Casado, Eliana
AU  - Hidalgo-Gutiérrez, Agustín
AU  - Raimundo, Nuno
AU  - González-García, Pilar
AU  - Acuña-Castroviejo, Darío
AU  - Escames, Germaine
AU  - López, Luis C
PY  - 2019
DO  - 10.1016/j.ebiom.2019.03.025
UR  - http://hdl.handle.net/10668/13746
T2  - EBioMedicine
AB  - The vast majority of mitochondrial disorders have limited the clinical management to palliative care. Rapamycin has emerged as a potential therapeutic drug for mitochondrial diseases since it has shown therapeutic benefits in a few mouse models of...
LA  - en
KW  - CoQ deficiency
KW  - Mitochondrial diseases
KW  - Mitochondrial encephalopathy
KW  - Mouse model
KW  - mTORC1
KW  - Animals
KW  - Autophagy
KW  - Cell Respiration
KW  - Disease Models, Animal
KW  - Gene Expression Profiling
KW  - Humans
KW  - Metabolomics
KW  - Mice
KW  - Mitochondria
KW  - Mitochondrial Diseases
KW  - Mitochondrial Encephalomyopathies
KW  - Phenotype
KW  - Sirolimus
KW  - Treatment Outcome
KW  - Ubiquinone
TI  - Rapamycin administration is not a valid therapeutic strategy for every case of mitochondrial disease.
TY  - research article
VL  - 42
ER  -